Basilea bins IPO, gets Sfr200m via CB/rights
The equity-linked market in Europe has been quiet since Total SA’s $1.2bn deal on November 25, but on Wednesday a very different deal was executed successfully by Basilea Pharmaceutica, a small and still unprofitable Swiss drug company.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: